TENAX THERAPEUTICS, INC. (TENX)
Data as of , from SEC Form 4 filings.
See up to 3 months of TENX. The 7-day demo opens the 1M and 3M ranges and puts TENX on your watchlist.
Start 7-day demoLatest TENX insider trades
About TENAX THERAPEUTICS, INC. (TENX)
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
- CHAPEL HILL, NC
- 16
- 1995
- XNAS
TENX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 11 | 2,765,725 | $4.93M |
TENX insider transactions (Form 4)
4125 Form 4 filings on record, the earliest from Dec 12, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Declan Doogan - Director | Open-market purchase | Common Stock | 53,000 | $1.92 | $102K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 6,000 | $1.88 footnote F1 | $11K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 4,850 | $1.82 footnote F2 | $9K | |
| ||||||
 Thomas R. Staab II - Officer | Open-market purchase | Common Stock | 5,675 | $1.94 footnote F1 | $11K | |
| ||||||
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 900,000 | $1.78 footnote F1 | $1.60M | |
| ||||||
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 403,571 | $1.79 footnote F1 | $723K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 179,058 | $1.80 footnote F2 | $322K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 187,704 | $1.80 footnote F3 | $338K | |
| ||||||
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 202,124 | $1.78 footnote F1 | $360K | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 716,369 | $1.77 footnote F2 | $1.27M | |
| ADAR1 Capital Management, LLC - 10% Owner | Open-market purchase | Common Stock | 107,374 | $1.75 footnote F3 | $188K | |
| ||||||
| Christopher Thomas Giordano - Officer | Option exercise | Stock Option (right to buy) | 8,500 | $0.00 | - | |
| Christopher Thomas Giordano - Officer | Option exercise | Common Stock | 219 | $3.55 footnote F1 | $777 | |
| Christopher Thomas Giordano - Officer | Option exercise | Common Stock | 8,500 | $5.94 footnote F1 | $50K | |
| Christopher Thomas Giordano - Officer | Option exercise | Stock Option (right to buy) | 219 | $0.00 | - | |
| ||||||
| Thomas R. Staab II - Officer | Grant or award | Common Stock | 10,000 footnote F1 | $0.00 | - | |
| Thomas R. Staab II - Officer | Grant or award | Stock Option (right to buy) | 450,000 | $0.00 | - | |
| ||||||
| Thomas McGauley - Officer | Option exercise | Stock Option (right to buy) | 50,000 | $0.00 | - | |
 Stuart Rich - Officer | Open-market purchase | Common Stock | 1,000 | $9.01 footnote F1 | $9K | |
| Stuart Rich - Officer | Open-market purchase | Common Stock | 1,500 | $9.08 footnote F2 | $14K | |
| Stuart Rich - Officer | Open-market purchase | Common Stock | 2,500 footnote F3 | $9.20 | $23K | |
| ||||||
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 538 | $7.59 footnote F3 | $4K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 1,612 | $7.75 footnote F1 | $13K | |
| Christopher Thomas Giordano - Officer | Open-market purchase | Common Stock | 455 | $7.51 footnote F2 | $3K | |
| ||||||
| Thomas McGauley - Officer | Open-market purchase | Common Stock | 5,000 | $7.23 footnote F2 | $36K | |
| Thomas McGauley - Officer | Open-market purchase | Common Stock | 2,000 | $7.34 footnote F1 | $15K | |
| Thomas McGauley - Officer | Open-market purchase | Common Stock | 1,000 | $7.35 | $7K | |
| ||||||
 June Sherie Almenoff - Director | Open-market purchase | Common Stock | 93 | $7.15 | $665 | |
| June Sherie Almenoff - Director | Open-market purchase | Common Stock | 1,900 | $7.52 footnote F1 | $14K | |
| ||||||
| Robyn Hunter | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Declan Doogan | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Michael H. Davidson | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| June Sherie Almenoff | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Gerald T. Proehl | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Christopher Thomas Giordano - Officer | Grant or award | Stock Option (right to buy) | 1,250,000 | $0.00 | - | |
| Stuart Rich - Officer | Grant or award | Stock Option (right to buy) | 500,000 | $0.00 | - | |
| Robyn Hunter | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Declan Doogan | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Michael H. Davidson | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| June Sherie Almenoff | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Gerald T. Proehl | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
Item 8.01, 9.01
Item 7.01, 9.01
Item 8.01, 9.01
Item 2.02, 9.01
TENX insider trading FAQ
What is the latest insider trade for TENX?
TENAX THERAPEUTICS, INC. (TENX) had 6 insider filings in the last 90 days, with the most recent on 2026-09-18. The full record for TENX runs to 25 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TENX stock?
11 insider purchases of TENX were filed in the last 90 days, totaling $4.93M.
How many insiders are selling TENX stock?
No insider sales of TENX were filed in the last 90 days.
Where can I see TENX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TENX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Declan Doogan view on EDGAR
- - Christopher Thomas Giordano view on EDGAR
- - Thomas R. Staab II view on EDGAR
- - ADAR1 Capital Management, LLC view on EDGAR
- - ADAR1 Capital Management, LLC view on EDGAR
- - ADAR1 Capital Management, LLC view on EDGAR
- - Christopher Thomas Giordano view on EDGAR
- - Thomas R. Staab II view on EDGAR
- - Thomas McGauley view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where TENX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TENX with a 7-day demo
- TENX on your watchlist
- Every TENX Form 4 filing on record
- Up to 3 months of TENX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
